The SafeSEQ CRC Tx panel is a clinical grade, ultra-sensitive liquid biopsy solution for the identification of gene mutations in KRAS, NRAS, BRAF, PIK3CA, and AKT1 to inform therapy selection by detecting established and emerging predictive markers, resistance mutations, and frequently occurring genetic alterations associated with colorectal cancer and other metastatic cancers.
Monitor anti-EGFR treatment response and disease dynamics:
Provides the ability to identify and monitor molecular alterations that may evolve under the influence of treatment exposure, and to examine RAS mutation status for rechallenge. By accurately monitoring disease response and clonal dynamics, the SafeSEQ Panel enables the informed adaptation of therapeutic strategies.
Detect tumor driver mutations prevalent in metastatic colorectal cancer (mCRC) patients: Determine eligibility for anti-EGFR antibody selection as well as inhibitors of BRAF, PI3K, and AKT1. SafeSEQ enables maximum identification of patients eligible for therapy. Less sensitive technologies can miss a significant subset of patients who may benefit from targeted therapy.
Monitor and determine therapy efficacy in metastatic cancer patients:
Determine the driver biomarkers of disease, i.e., pancreatic cancer (KRAS); and malignant melanoma (BRAF and NRAS).
The SafeSEQ CRC Tx Panel is CE marked for IVD use and CLIA-validated for use in clinical trials.